Skip to main content
. 2022 Mar 1;15:673–683. doi: 10.2147/DMSO.S351492

Figure 1.

Figure 1

Comparison of liver activity score and fibrosis stage distributions between MAFLD-CHB and non-MAFLD-CHB groups under the NASH CRN system, stratified by HBeAg status (A) Comparison of liver activity score distribution; (B) Comparison of liver fibrosis stage distribution; (C) Comparison of proportion of A ≥3; (D) Comparison of proportion of F ≥2; MAFLD-CHB, defined as patients fulfilling the criteria for both MAFLD and CHB; Non-MAFLD-CHB, defined as patients who met the diagnostic criteria for CHB but did not meet the diagnostic criteria for MAFLD.

Abbreviations: MAFLD, metabolic associated fatty liver disease; CHB, chronic hepatitis B; NASH CRN, the Nonalcoholic Steatohepatitis Clinical Research Network; HBeAg, hepatitis B e antigen; A, liver activity score; F, fibrosis stages; *p < 0.05, **p < 0.01, and ***p < 0.001.